NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

Although there was consistent evidence of NALIRIFOX benefit versus Gem + NabP irrespective of age, survival outcome benefits did not reach statistical significance in some of the smaller subgroups analyzed [≥70 years ( n = 217), 70 to <75 years ( n = 153), ≥75 years ( n = 64), and ≥80 years ( n = 12)] ( Supplementary Table S2 , available at https://doi.org/10.1016/j.esmoop.2025.106043 ).

also in 111,027 other papers